NEWTOWN, Pa., June 20, 2013 /PRNewswire/ -- Encuity Research, the market research and analytics subsidiary of Campbell Alliance, today released the results of its second annual ASCO Impact Report. Oncologists surveyed highlighted new treatments for melanoma and cervical cancer as the most important subjects of new clinical information at the 2013 ASCO conference. New treatments for melanoma, with an emphasis on PD-1 treatments, were cited by 31% of respondents, while advances in the treatment of cervical cancer, particularly Genentech/Roche's Avastin®, were cited by 20% of respondents.

The ASCO Impact Report is based on an survey of 100 oncologists attending the 2013 annual meeting of the American Society of Clinical Oncologists (ASCO). The report is designed to gauge physician perceptions about the conference and to assess how ASCO may impact future prescribing behavior.

Oncologists who attended ASCO gave information presented on bevacizumab (Avastin) the highest overall ratings at ASCO, with 66% of attendees rating it as very or extremely valuable. Information on Bayer/Onyx's sorafenib (Nexavar®) in thyroid cancer received the second highest ratings (58%).

When asked which companies provided the most valuable information at the conference (unaided), Genentech was mentioned by far the most frequently (84% of attendees), followed by Bristol-Myers Squibb with 43% of mentions. Oncologists named Millennium most often as an up-and-coming company in the treatment of cancer (13% of mentions); Seattle Genetics and Sanofi followed.

Physicians who attended the 2013 ASCO meeting reported that the conference had significantly less of an impact on their future behavior than the 2012 conference. Just 16% of attendees reported that they are likely to change patient treatments based on this year's ASCO conference, compared with 40% in 2012. As one respondent clarified, "(I'm) mainly waiting for new drugs to come out. Nothing to change current practice."

Nonetheless, 2013 ASCO attendees found the conference to be valuable overall. Half of physicians rated the event as very or extremely valuable, with 86% reporting that it was equal to or more valuable than the 2012 conference.

"You can tell a great deal about the sentiments of oncologists following their experiences at ASCO given the level of data included in our report. Those feelings translate in prescribing behaviors throughout the year, and this information is naturally of high interest to pharmaceutical and biotech companies developing and commercializing products in this space," stated Dave Johnson, Vice President, Encuity Research.

The ASCO Impact Report provides an encompassing view of ASCO attendees' intent to change treatment plans, their perceptions of clinical information presented, and their ratings of information offered by pharmaceutical and biotech companies. For more information and to download a copy of the ASCO Impact Report, please visit http://www.encuity.com/ASCO.

About Encuity Research

Encuity Research is the market research and analytics subsidiary of Campbell Alliance. Encuity's team of skilled market research professionals provides answers that biopharmaceutical leaders need to make critical decisions at enterprise, portfolio, and product levels. Its services span five key areas, including custom qualitative and quantitative market research and analytics, syndicated market research, promotional message tracking, and key opinion leader (KOL) influence mapping. For more information on Encuity and its services, please visit http://www.encuity.com.

About Campbell Alliance

Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. Campbell Alliance is an industry leader in biopharmaceutical and medical technology consulting. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Clinical Development, Commercial Effectiveness, Corporate Development, Medical Affairs, and Pricing and Market Access. From its locations in New York City; Raleigh, NC; Parsippany, NJ; Somerset, NJ; Newtown, PA; Los Angeles; San Francisco; Chicago; Boston; Philadelphia; London; and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.

About inVentiv Health

inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv's 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

Media Contact

James Forte
Vice President, Marketing
(919) 844-7100, x7195
jforte@campbellalliance.com

SOURCE Encuity Research


 
 
Information Supplied by: